June 08, 2025
5 min watch
Key takeaways:
- Wearable applied sciences at the moment within the pipeline may help in managing diabetes comorbidities.
- Nonetheless, fast evolution on this house creates problem in conducting giant randomized medical trials.
PHILADELPHIA — Present applied sciences, and people within the pipeline and past, may advance the administration of diabetes comorbidities, George Grunberger, MD, FACP, FACE, stated throughout a presentation on the Coronary heart in Diabetes CME Convention.
Steady glucose monitoring, wearable units and different rising applied sciences have the potential to not solely enhance glycemic management but additionally cut back the danger for diabetes-related problems, based on Grunberger, who’s chairman of the Grunberger Diabetes Institute in Bloomfield Hills, Michigan.
At Coronary heart in Diabetes, Healio spoke with Grunberger talks in regards to the affect of know-how on the administration of diabetes and diabetes comorbidities, challenges with conducting trials and extra.
Editor’s observe: Watch the Healio Unique video interview under.
CGM confers advantages; extra knowledge wanted
Grunberger emphasised the constructive affect CGM has had on diabetes administration, noting that the information present priceless insights for each well being care professionals and sufferers.
“It’s wonderful what discussions you possibly can have if you simply have a look at a day, every week or a month in a profile of glycemic excursions on your sufferers,” Grunberger stated. “Likewise, sufferers themselves fairly often change their way of life, even with out [a health care professional’s] enter.”
Regardless of the advantages, steerage is missing on managing diabetes for folks with sure comorbidities.
For instance, Grunberger stated knowledge are missing on the accuracy of CGM is for folks with diabetes and end-stage kidney illness. Nonetheless, CGM has some advantages on this affected person inhabitants, based on Grunberger.
“CGM has been accepted as a option to monitor [these patients],” Grunberger stated. “It’s been proven, even in folks on dialysis, that general high quality of life and general administration adjustments simply utilizing the CGM.”
Extra analysis is required on the potential for know-how to help in managing sufferers with different comorbidities, he stated.
Applied sciences within the pipeline
Grunberger highlighted a number of applied sciences that might rework diabetes administration sooner or later — from units that observe cardiac biomarkers and alert the affected person of cardiac abnormalities to sensible contact lenses that might assist deal with diabetic retinopathy.
“There’s a wide range of neuromodulation units that might enhance blood circulate to nerves and hopefully have an effect on diabetic neuropathy,” Grunberger stated. “There are a number of wearable sensors for the microbiome which may hopefully regulate [insulin] sensitivity.”
Gene modifying to deal with diabetes problems and stem cell remedy to deal with diabetic neuropathy might also be used sooner or later.
Analysis challenges
Grunberger stated that whereas the longer term is vibrant for rising applied sciences, gathering randomized managed knowledge on their efficacy is troublesome because of how briskly know-how is altering.
“In the event you use drugs, you possibly can randomize tens of 1000’s of individuals into double-blind or potential trials, and get arduous outcomes,” Grunberger stated. “Utilizing [new] applied sciences, that are quickly evolving, makes it very troublesome to do a big examine.”
For extra info:
George Grunberger, MD, FACP, FACE might be reached at grunberger@gdi-pc.com.
Sources/Disclosures
Collapse
Healio Interviews
Disclosures:
Grunberger stories talking for Abbott Diabetes Care, Eli Lily and Sanofi, and advising for Cequr and MannKind.
